Every eight shares of Biomerica’s pre-split common stock issued and outstanding will be automatically reclassified as and converted into one new share of Biomerica’s common stock on Monday.
The latest approval aligns with Biomerica’s strategy to broaden its presence in the Middle East, a region where prostate cancer is increasingly viewed as a pressing health issue.